During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.
The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.
The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
More accommodating regulation and new funding may propel new diagnostics companies across the valley of death to commercial returns.
Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.
DNAe will combine its semiconductor DNA sequencing technology with nanoMR's PCS technology for a complete blood-to-result solution.